Showing 301-310 of 9369 results for "".
Cutaneous Superficial Leiomyosarcoma: A Treatment Conundrum
https://practicaldermatology.com/topics/general-topics/cutaneous-superficial-leiomyosarcoma-a-treatment-conundrum/21504/Select presentations given by dermatology residents at Cosmetic SurgeryThe Evidence for Slow- and Fast-growing Melanomas
https://practicaldermatology.com/topics/skin-cancer-photoprotection/1109_06-php/22058/Recent findings support the existence of slow-growing melanomas, offering a possible explanation for anomalies in melanoma incidence reporting.Seborrheic Dermatitis Update: A Review of the Etiology and Treatment of Seborrheic Dermatitis
https://practicaldermatology.com/programs/practical-dermatology/seborrheic-dermatitis-update-a-review-of-the-etiology-and-treatment-of-seborrheic-dermatitis/24003/Seborrheic dermatitis (SD) is an inflammatory skin condition that often involves flaky, erythematous patches on sebum-rich areas of the body such as the face and scalp.1 At least 50 million Americans have a form of seborrheic dermatitis on the scalp, more commonly known as dandruff. SD presents in aThe State of Private Equity in 2024: Impact on the Practice of Dermatology
https://practicaldermatology.com/columns/practice-management/state-private-equity-2024-impact-practice-dermatology/27173/Physician Growth Partners recently published a white paper, “State of Dermatology Private Equity,” that evaluated market trends, strategies, and more. Practical Dermatology® spoke exclusively with CEO Michael Kroin about how the evolution of private equity is impacting the everyday practitioner andThe Future Is Now: Technology for Skincare
https://practicaldermatology.com/topics/practice-management/the-future-is-now-technology-for-skincare/20814/AI and AR are changing the way skin care is prescribed.Study Examines Association Between Childhood BMI and Risk of Developing IMSDs
https://practicaldermatology.com/series/dermwire-tv/study-examines-association-between-childhood-bmi-and-risk-of-developing-imsds/27004/In this week's DermwireTV, a new study examines the relationship between childhood BMI and skin diseases; phase 3 data sheds new light on dupilumab’s effect on inflammatory biomarkers in pediatric AD patients; and the president and CEO of Evolus discusses trends in the injectables market.Science of Skincare Summit 2024: On the FDA Approval of Emrosi for Rosacea
https://practicaldermatology.com/conferences/science-skincare-summit-2024/science-of-skincare-summit-2024-on-the-fda-approval-of-emrosi-for-rosacea/29276/At the Science of Skincare Summit in Austin, Practical Dermatology caught up with Chief Medical Editor Neal Bhatia, MD, and James Del Rosso, DO, a dermatologist and Editor in Chief of Clinical Dermatology at the Journal of Clinical and Aesthetic Dermatology (JCAD), who shared insights and thoughts oPsleep: Psoriasis and Sleep
https://practicaldermatology.com/topics/psoriasis/psleep-psoriasis-and-sleep/29075/The “invisible” impacts of psoriasis are those not directly seen on examination. These include itch, pain, fatigue and sleep dysfunction, which may be improved by our systemic therapies. However, there is a gap between the patients’ reporting of these experienced invisible impacts and their physiciaDr. Battle on Skin of Color Update and Minimizing, Treating Complications from Energy-Based Devices
https://practicaldermatology.com/topics/skin-of-color/dr-battle-skin-color-update-and-minimizing-treating-complications-energy-based-devices/28655/Eliot Battle, MD, discusses the growth of Skin of Color Update, minimizing and treating complications when treating patients of skin of color, and integrating energy-based devices into your practice.Hidradenitis Suppurativa: A Patient’s Perspective
https://practicaldermatology.com/topics/rare-disease/hidradenitis-suppurativa-a-patients-perspective/27171/Adam Friedman, MD, FAAD, presents a first-hand account of a patient living with hidradenitis suppurativa (HS).